Learn how the optimized, scalable infrastructure provided by Indica Labs Cloud Services enables the rapid development and robust collaboration of our AI Diagnostics group, powering the next generation of automated AI-based decision support tools.
Cloud Services and AI Diagnostics Case Study Read More »
Learn more about Nottingham University Hospitals NHS Trust’s transition to digital pathology and how HALO AP® has played a pivotal role in improving diagnostic efficiency and patient care.
HALO AP® NUH Case Study Read More »
Discover how the seamless integration of third-party image analysis algorithms, such as DeepDx from Deep Bio, with HALO AP® can benefit your lab.
HALO AP® Deep Bio Case Study Read More »
Read about the development and validation of an AI-based PD-L1 scoring algorithm for HALO AP®.
Learn more about the development and validation of an AI-based molecular pathology algorithm for estimating tumour cells in lung adenocarcinoma.
Explore Breast IHC AI, a deep learning-based workflow for evaluation of breast cancer.
Check-out exciting new features and functionalities in the latest release of HALO AP®, AI-powered digital pathology platform for diagnostics
HALO AP® 2.4 Features and Functionalities Read More »
Migrating from Aperio eSlide Manager to Indica Labs HALO Image Management Systems
Migrating from Aperio eSlide Manager to Indica Labs HALO Image Management Systems Read More »
26 – 28 June 2025 | Visit us at booth #19 for a live demonstration of the latest developments across our HALO clinical and life science products on June 26-28 or prebook a meeting at our booth.
Albuquerque, NM, April 30, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today an update to their Breast IHC AI suite, an image analysis tool used for the quantification of HER2, ER, PR, and Ki67 within AI-identified, tumor regions, of breast cancer tissue specimens. The HER2 algorithm will now include functionality for the detection of low and ultralow HER2 expression in breast cancer.
